Follow-on roundup: ImmunoGen, Mirati, Zymeworks, Viking, OptiNose
ImmunoGen Inc. (NASDAQ:IMGN), Mirati Therapeutics Inc. (NASDAQ:MRTX), Zymeworks Inc. (NYSE:ZYME; TSX:ZYME), Viking Therapeutics Inc. (NASDAQ:VKTX) and OptiNose Inc. (NASDAQ:OPTN) each priced follow-ons, raising a total of more than $465 million.
ImmunoGen raised $150.7 million through the sale of 13.7 million shares at $11 in an upsized follow-on underwritten by J.P. Morgan, Goldman Sachs, Cowen, Canaccord Genuity and H.C. Wainwright. The price is a 4% discount to ImmunoGen's closing price of $11.47 on June 5, when it proposed after hours to sell 12 million shares. The company is conducting the Phase III FORWARD I study of mirvetuximab soravtansine (IMGN853) to treat ovarian cancer; the therapy is an antibody-drug conjugate comprising a folate receptor 1 (FOLR1; FR-alpha)-targeting mAb linked to ImmunoGen's DM4 cytotoxic agent...